Early detection of heart failure with preserved ejection fraction (HFpEF) is critical to improving outcomes and slowing disease progression. Panelists noted that many patients remain undiagnosed until symptoms become advanced, limiting treatment effectiveness. Identifying individuals at high risk—particularly those with diabetes, obesity, and hypertension—through routine screening can enable earlier intervention.

The discussion highlighted the growing role of biomarkers, imaging, and digital monitoring in early detection. Echocardiographic parameters, natriuretic peptide levels, and wearable device data may together reveal subclinical changes before overt symptoms develop. Integrating these tools into primary care could allow earlier recognition and referral to specialists.

Panelists agreed that prevention must start before symptom onset. Lifestyle management, aggressive risk factor control, and early use of evidence-based therapies such as sodium-glucose transporter 2 inhibitors and mineralocorticoid receptor antagonists may alter disease trajectory. Building systems that combine technology, education, and proactive care was seen as essential to reshaping HFpEF outcomes.